Alzheimer's Drug Discovery Foundation

Krista Lanctot, PhD: Managing Patients with Agitation

September 30, 2018

Lanctôt advised ruling out any possible underlying medical conditions that could be causing it, including pain, as well as starting with any non-pharmacologic interventions.

Irina Pikuleva, PhD: Activating CYP46A1 with Efavirenz

September 28, 2018

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University spoke about the beginnings of her work with efavirenz.

Paul Newhouse, MD: Attacking Different Targets in Alzheimer

September 27, 2018

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine shared his feelings on the early phase treatments.

Howard Fillit, MD: The Importance of Biomarkers for Alzheimer Disease

September 26, 2018

Fillit spoke about remaining need for additional biomarkers in Alzheimer, and what has been developed in recent years.

Krista Lanctot, PhD: Addressing Alzheimer Disease Agitation

September 25, 2018

The psychiatry and pharmacology professor at the University of Toronto and senior scientist at Sunnybrook Research Institute spoke about the use of cannabinoids to treat agitation in Alzheimer.

Irina Pikuleva, PhD: Using Efavirenz in Alzheimer Disease

September 24, 2018

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.